Here's Gilead Sciences' Great COVID-19 Opportunity That You'll Really Want to Watch
Plenty of drugmakers are developing potential treatments for COVID-19. But -- so far, at least -- only Gilead Sciences (NASDAQ: GILD) can claim a COVID-19 therapy that has sailed through late-stage testing. Gilead's remdesivir won FDA Emergency Use Authorization (EUA) and received conditional approval in Europe as a treatment for the novel coronavirus disease.
Remdesivir appears to be effective in treating hospitalized patients with COVID-19. But there's another big COVID-19 opportunity for Gilead that you'll really want to watch.
Image source: Getty Images.
Source Fool.com
